SEQUELLA, INC.

Basic Information

9610 MEDICAL CENTER DR, STE 200
ROCKVILLE, MD, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 125129606
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. A New Therapeutic Regimen for MDR-TB

    Amount: $565,341.00

    DESCRIPTION (provided by applicant): World Health Organization (WHO) declared tuberculosis (TB) a global health emergency; a distinction never accorded another disease. Two billion people are infected ...

    SBIR Phase I 2012 Department of Health and Human Services
  2. Targeting MtrAB of M. tuberculosis

    Amount: $587,856.00

    DESCRIPTION (provided by applicant): Tuberculosis (TB) has a massive impact on global health. The World Health Organization estimates that one- third of all people worldwide harbor latent TB infection ...

    STTR Phase I 2011 Department of Health and Human Services
  3. SQ109 for treatment of MDR-TB

    Amount: $599,797.00

    DESCRIPTION (provided by applicant): SQ109 is a small molecule, orally active drug and is a new drug candidate in clinical development for the treatment of all forms of tuberculosis (TB), including mu ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. Advancing lead dipiperidine compound into preclinical development

    Amount: $305,054.00

    DESCRIPTION (provided by applicant): In our previous work we identified a series of potent cell-wall inhibiting dipiperidines that are structurally unrelated to any existing antitubercular drugs. Afte ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. SQ641, new drug candidate to treat NTM infections

    Amount: $594,661.00

    DESCRIPTION (provided by applicant): Mycobacterium avium complex (MAC) and M. abscessus (MAB) are the two most common nontuberculous mycobacteria (NTM) that cause human disease, and the incidence of N ...

    SBIR Phase I 2009 Department of Health and Human Services
  6. Novel mycobacterial translocase I inhibitors- a new class of anti-TB drugs

    Amount: $2,332,323.00

    DESCRIPTION (provided by applicant): Physicians treating tuberculosis (TB) today are in desperate need of new, efficient, and effective antibiotics to improve both time of treatment and durability of ...

    SBIR Phase II 2008 Department of Health and Human Services
  7. Development of a phage-based nucleic acid amplification diagnostic for the rapid

    Amount: $244,346.00

    DESCRIPTION (provided by applicant): In April 1993, the World Health Organization (WHO) declared tuberculosis (TB) a global health emergency, a distinction never accorded another disease. Two billion ...

    SBIR Phase I 2008 Department of Health and Human Services
  8. Novel mycobacterial translocase I inhibitors--a new class of anti-TB drugs

    Amount: $228,016.00

    DESCRIPTION (provided by applicant): Recent statistics lists tuberculosis (TB) as a serious infectious disease that kills nearly 2 million people worldwide each year. One third of the world's populati ...

    SBIR Phase I 2006 Department of Health and Human Services
  9. Dipiperidines as a new class of anti-TB drug

    Amount: $299,475.00

    DESCRIPTION (provided by applicant): The overall aim of this application is to characterize a new class of drugs to treat tuberculosis (TB) that are structurally unrelated to any existing anti-TB dru ...

    SBIR Phase I 2004 Department of Health and Human Services
  10. A Rapid Lateral Flow Test for TB in Nonhuman Primates

    Amount: $0.00

    DESCRIPTION (provided by applicant): The goal of this project is to develop and bring to market a new diagnostic test for tuberculosis (TB) in nonhuman primates. The new diagnostic is based upon the ...

    SBIR Phase I 2003 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government